Homburger advised PPF Group in the sale of NBE-Therapeutics to Boehringer Ingelheim

On December 10, 2020, Boehringer Ingelheim announced the signing of a binding agreement on the acquisition of all shares in NBE-Therapeutics AG. The total transaction value is EUR 1.18 bn and includes contingent clinical and regulatory milestones.

NBE-Therapeutics, headquartered in Basel, Switzerland, is a private, clinical-stage Swiss biotechnology company focused on antibody-drug conjugates and advancing targeted cancer therapies derived from its immune stimulatory iADC™ platform.

Homburger acted as legal advisor to the seller PPF Group, an international investment group rooted in the Czech Republic. The Homburger team was led by partner Dieter Gericke (Corporate / M&A) and comprised partner Reto Heuberger (Tax) and associate Marc Hanslin (Corporate / M&A).